Botox developer rues missing out on billions

Botox developer Alan Scott says he rues the day he handed over rights to the best-selling wrinkle-smoothing drug to a US company for just $4.5 million, saying he might have become a billionaire.

Botox has become a front-line weapon in cosmetic medicine for erasing wrinkles -- while therapeutic applications of the drug are being used to help a wide variety of disorders from to .

"If I knew (how big it would become), I would have never given it to the drug company in 1991," Dr Alan Scott told the Times of India in an interview published on Monday.

"At present Botox is being used for over 100 disorders besides aesthetic applications," Scott said in New Delhi where he was en route to a conference in southern India.

The San Francisco opthalmologist said he got around $4.5 million for handing over the rights to the drug to the California-based company Allergan which "was then a satisfactory deal."

"But if I had held on to Botox, maybe I could have made a billion dollars a year now," Scott said.

Botox, which makes muscles relax, is a purified form of a nerve poison produced by a bacteria that causes a disease that paralyses muscles and can be fatal.

Botox was first approved in 1989 to treat two eye muscle disorders -- uncontrollable blinking and misaligned eyes.

"Initially when I developed it, I knew it could do wonders for neurological disorders. However, I had absolutely no idea it could work so well as a cosmetic agent," said Scott, who initially called the Oculinum.

The big cosmetic breakthrough came when Canadian Dr. Jean Carruthers noticed her patients were starting to lose their frown lines and published a study in 1992.

A decade later Botox was approved as a frown fixer by the US and now it is used in 80 countries.

Does Scott worry about any side-effects from the widespread use of ?

"It is not clear what will happen after decades of use. Maybe the facial muscles will weaken and sag. But we know that it works in reducing facial wrinkles," he said.

"Most women don't care what will happen years later. They just want the wrinkles to disappear now."

add to favorites email to friend print save as pdf

Related Stories

Botox reduces wrinkles even in less frequent doses

Apr 26, 2010

Patients can decrease the frequency of Botox Cosmetic injections after approximately two years and still receive most of the same wrinkle-smoothing cosmetic benefits, according to new research at Oregon Health & Science University.

FDA approves Botox for migraine headaches

Oct 15, 2010

(AP) -- Federal health officials approved the wrinkle-smoothing injection Botox for migraine headaches on Friday, giving drugmaker Allergan clearance to begin marketing its drug to patients with a serious history of the ...

Study questions botox use for migraines

Feb 08, 2011

The anti-wrinkle drug Botox, which has been licensed in some countries as a treatment for chronic migraine, has negligible effect against these headaches, a study published on Tuesday said.

US approves Botox for bladder control

Aug 24, 2011

The face-freezing pharmaceutical injection Botox gained another medical use on Wednesday when the US government approved it for use in some patients with overactive bladder.

Dysport the newest wrinkle-stopping drug to hit market

May 13, 2009

There's a new wrinkle remover on the market. Late last month, the U.S. Food and Drug Administration sanctioned Dysport for cosmetic and therapeutic use. Like Botox, it's an injectable drug derived from a botulinum toxin. ...

Recommended for you

Supermaterial gives rejected drugs a new chance

10 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments